Fluoguide Q3 2023: Spoilt for choice - Redeye

Redeye comments on Fluoguide’s Q3 2023 report, with the company reporting two solid phase II readouts since our last update. We expect Fluoguide to present its later-stage clinical development plan for FG001 in coming months and do some housekeeping in our model.

Länk till analysen i sin helhet: https://www.redeye.se/research/964355/fluoguide-q3-2023-spoilt-for-choice?utm_source=finwire&utm_medium=RSS